PR Newswire Clinical TrialsOriginal article
Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
Phase 3positivedenecimigPositive
AI Analysis
Summary
Novo Nordisk announced positive interim Phase 3 FRONTIER4 extension study results for denecimig (Mim8) in hemophilia A, demonstrating long-term safety and efficacy across multiple subcutaneous dosing regimens in patients of all ages and disease severities.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Positive results in long-term safety and efficacy demonstrated in FRONTIER4 extension study across once-weekly, once-every-two-weeks, and once-monthly dosing
Importance:7/10
Sentiment:
0.75
hemophilia Adenecimigphase 3FRONTIER4ISTH 2026subcutaneous
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 11, 2026 12:05 PM